MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a pooled analysis of three Phase 3, randomized, placebo-controlled trials (Studies 301, 302 and 304) evaluating the safety and efficacy of once-daily Aptiom® (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures. Key findings from the pooled Phase 3 studies showed that APTIOM demonstrated statistically significant improvements in standardized seizure frequency for 800 mg and 1,200 mg once-daily dosages versus placebo and higher responder rates (50% and 75% reductions) with APTIOM treatment versus placebo at the same dosages. These results were presented at the 67th Annual Meeting of the American Epilepsy Society (AES) taking place in Washington, D.C., December 6-10, 2013.
Help employers find you! Check out all the jobs and post your resume.
